Mavoglurant: all 26 studies that test it
Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy DrinkersRecruitingNCT06136195Phase 1
- Mavoglurant in Alcohol DrinkingCompletedNCT03327792Phase 1Results posted
- Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)CompletedNCT03242928Phase 2Results posted
- AFQ056 for Language Learning in Children With FXSCompletedNCT02920892Phase 2Results posted
- Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) TherapyTerminatedNCT01813019Phase 2Results posted
- Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)TerminatedNCT01433354Phase 2/3Results posted
- Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X SyndromeCompletedNCT01357239Phase 2Results posted
- Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X SyndromeTerminatedNCT01348087Phase 2Results posted
- Phase1, STP7 Cocaine Drug-Drug Interaction StudyCompletedNCT06273540Phase 1
- Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor MavoglurantCompletedNCT05203965Early Phase 1
- Study to Assess Safety, Tolerability, and Interactions of Cocaine and Oral AFQ056WithdrawnNCT04771143Phase 1
- Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHNCompletedNCT03341715Early Phase 1
- Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasCompletedNCT01491932Phase 2
- Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasCompletedNCT01491529Phase 2
- Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)CompletedNCT01482143Phase 1
- A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy SubjectsCompletedNCT01456663Phase 1
- An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy SubjectsCompletedNCT01442259Phase 1
- Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasCompletedNCT01385592Phase 2
- Safety and Efficacy of AFQ056 in Adult Patients With Fragile X SyndromeCompletedNCT01253629Phase 2
- Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced DyskinesiasCompletedNCT01173731Phase 2
- Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced DyskinesiaCompletedNCT01092065Phase 2
- Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing ChoreaTerminatedNCT01019473Phase 2
- Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's DiseaseCompletedNCT00986414Phase 2
- Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease PatientsCompletedNCT00888004Phase 2
- Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopaCompletedNCT00582673Phase 2
- Effects of AFQ056 and Baclofen on Meal-Induced Gastroesophageal RefluxCompletedNCT00414856Phase 1